80 results about "Premature birth" patented technology

The present invention provides methods of treating one or more complications of premature birth suffered by premature infants, comprising administering to the premature infant umbilical cord blood stem cells and, optionally, placental stem cells. The present invention also provides methods of combining and administering, and compositions comprising, umbilical cord blood stem cells, particularly autologous cord blood cells, and placental stem cells for the treatment of premature infants.

The invention relates to a combined assay kit for premature birth of a pregnant woman and fetal membrane premature rupture, which comprises a premature birth and fetal membrane premature rupture immunochromatographic assay test strip or comprises a premature birth immunochromatographic assay test strip and a fetal membrane premature rupture immunochromatographic assay test strip. More preferably, the combination mat and the nitrocellulose membrane of the premature birth immunochromatographic assay test strip are respectively provided with a premature birth assay immunolabelling antibody and a premature birth assay antibody; the combination mat and the nitrocellulose membrane of the fetal membrane premature rupture immunochromatographic assay test strip are respectively provided with a fetal membrane premature rupture assay immunolabelling antibody and a fetal membrane premature rupture assay antibody, or the immunolabelling antibodies and the antibodies are respectively coated onto the combination mats and the nitrocellulose membranes of the premature birth and fetal membrane premature rupture immunochromatographic assay test strip. The combined assay kit for the premature birth of the pregnant woman and the fetal membrane premature rupture is capable of simultaneously diagnosing the premature birth and the fetal membrane premature rupture through primary sampling, is simple and convenient in application, and further, is capable of improving the accuracy of premature birth diagnosis. A powerful basis is provided for the next accurate treatment by combined assay results. The combined assay kit for the premature birth of the pregnant woman and the fetal membrane premature rupture is suitable for popularization and application in a large scale.

The present invention is related to the use of pyrrolidine esters of formula (I) for the treatment and / or prevention of premature labor, premature birth and dysmenorrhea. In particular, the present invention is related to the use of pyrrolidine esters of formula (I) to modulate, notably to antagonize the oxytocin receptor. The present invention is furthermore related to novel pyrrolidine esters. X is selected from the group consisting of CR6R7, NOR6, NNR6R7; R is selected from the group comprising or consisting of C1–C6 alkyl, C2–C6 alkenyl, C2–C6 alkynyl, saturated or unsaturated 3–8-membered cycloalkyl which may contain 1 to 3 heteroatoms selected of N, O, S, aryl, heteroaryl, C1–C6-alkyl aryl, C1–C6-alkyl heteroaryl. R1 is selected from the group comprising or consisting of C1–C6-alkyl, C2–C6-alkenyl, C2–C6-alkynyl, aryl, heteroaryl, 3–8-membered cycloalkyl, acyl, C1–C6-alkyl aryl, C1–C6-alkyl heteroaryl, said cycloalkyl or aryl or heteroaryl groups may be fused with 1–2 further cycloalkyl or aryl or heteroaryl group

The invention provides a neonatal infant incubator apparatus (10) and a control system module (17), and methods and systems for using the control system module to control the microenvironment of the contained space (16) of the infant incubator apparatus (10). The neonatal infant incubator apparatus (10) including a collapsible frame (12) and a disposable housing (14) to create a closed contained space (16) with a controlled microenvironment. The control system module (17) is comprises a battery (32) and is configured to operate with low voltage; the control system module (17) configured to control the microenvironment, including regulating the temperature and gas composition, of the contained space (16), and includes an air circulation system (72) in air and / or fluid communication with thecontained space (16). The systems, apparatus and methods are suitable for containing a full-term or premature infant in need of care in areas where power sources are limited, including e.g., rural orremote regions, third world countries, in a regular clinical setting and / or for transportation of the infant.

The present invention relates to triazole derivatives of formula (I) notably for use as pharmaceutically active compounds, as well as pharmaceutical formulations containing such triazole derivatives. Said triazoles are useful in the treatment and / or prevention of preterm labor, premature birth, dysmenorrhea, inappropriate secretion of vasopressin, congestive heart failure, arterial hypertension, liver cirrhosis, nephrotic syndrome and ocular hypertension. In particular, the present invention is related to triazole derivatives displaying a substantial modulatory, in particular antagonistic activity, of the oxytocin and / or vasopressin receptor. More preferably, said compounds are useful in the treatment and / or prevention of disease states mediated by oxytocin and / or vasopressin. The present invention is furthermore related to novel triazole derivatives as well as to methods of their preparation.

The invention provides a nutrient, formula milk powder for a pregnant woman and application of the formula milk powder. The nutrient comprises numerous vitamins and multiple trace elements, so that requirements of the pregnant woman and a fetus on vitamins and trace elements can be met. The nutrient is characterized in that folic acid, iron and lactoferrin are simultaneously added to the nutrient, so that absorption of the pregnant woman to iron can be promoted, and anemia, caused by competition of the fetus for serum iron, of the pregnant woman can be improved. The formula milk powder comprises the nutrient, whey powder, whole milk powder, skimmed milk powder, prebiotics, lactoalbumin powder, calcium carbonate and maltodextrin. Various nutrient substances are scientifically matched, so that requirements of the pregnant woman and the fetus on various nutrient substances can be met; particularly, the folic acid, the iron and the lactoferrin are simultaneously added, so that the phenomenon of premature birth or underweight of the fetus caused by anemia of the pregnant woman can be effectively prevented.

The present invention relates to sulfanilide derivatives of formula (I), in which R1 and R2 are optionally substituted aryl and heteroaryl groups and the other variables are as defined in the claims, for use as pharmaceutically active compounds, as well as pharmaceutical formulations containing such sulfanilide derivatives. Said derivatives are useful in the treatment and / or prevention of preterm labor, premature birth, dysmenorrhea, inappropriate secretion of vasopressin, congestive heart failure, arterial hypertension, liver cirrhosis, nephrotic syndrome and ocular hypertension. In particular, the present invention is related to sulfanilide derivatives displaying a substantial modulatory, in particular antagonistic activity, of the oxytocin and / or vasopressin receptor. More preferably, said compounds are useful in the treatment and / or prevention of disease states mediated by oxytocin and / or vasopressin, including preterm labor, premature birth, dysmenorrhea, inappropriate secretion of vasopressin, congestive heart failure, arterial hypertension, liver cirrhosis, nephrotic syndrome and ocular hypertension. The present invention is furthermore related to novel sulfanilide derivatives as well as to methods of their preparation.

The present invention is related to thiazolidine carboxamide derivatives of formula (II) for the treatment and / or prophylaxis of preterm labor, premature birth, dysmenorrhea and for stopping labor prior to cesarean delivery. G is selected from the group consisting of C1-C6-alkyl aryl, C1-C6-alkyl heteroaryl, C1-C6 Alkyl cycloalkyl, C1-C6-alkyl heteroaryl, aryl, heteroaryl, C3-C8-cycloalkyl or -heterocycloalkyl, said cycloalkyl or aryl or hetetoaryl groups may be fused with cycloalkyl or aryl or heteroaryl groups. R1 is selected from the group consisting of aryl, heteroaryl, C3-C8-cycloalkyl or -heterocyclo-alkyl, said (hetero)cycloalkyl or aryl or heteroaryl groups may be fused with (hetero)cycloalkyl or aryl or heteroaryl groups. R2 is selected from the group consisting of H, carboxy, acyl, alkoxycarbonyl, aminocarbonyl, C1-C5-alkyl carboxy, C1-C5-alkyl acyl, C1-C5-alkyl alkoxycarbonyl, C1-C5-alkyl aminocarbonyl, C1-C5-alkyl acyloxy, C1-C5-alkyl acylamino, C1-C5-alkyl ureido, C1-C5alkyl amino, C1-C5-alkyl alkoxy, C1-C5-alkyl sulfanyl, C1-C5-alkyl sulfinyl, C1-C5-alkyl sulfonyl, C1-C5-alkyl sulfonylamino, C1-C5-alkyl sulfonyloxy, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, aryl, heteroaryl, C3-C8-cycloalkyl, heterocycloalkyl, C1-C6-alkyl aryl, C2-C6-alkyl heteroaryl, C1-C6-alkyl cycloalkyl, C1-C6-alkyl heterocycloalkyl, C2-C6-alkenyl aryl, C2-C6-alkenyl heteroaryl, C2-C6-alkynyl aryl, or C2-C6-alkynyl heteroaryl.